Arch Biopartners Inc V.ARCH

Down 30% off the highs

[stocksarefun]

Anybody have insight into where this ends? We're assuming third party data news is the kicker here. But as the share price continues to slide, doesn't it imply that our ability to uplist becomes increasingly difficult?

CEO clearly wanted to send a signal to the market that everything is ok with that 2500 share purchase on Wednesday last week. Didn't work. Still in freefall. 

Not nervous, but concerned, as I still doubt anyone here or their respective circles of friends/family haven't sold a share. Most that I know have actually bought more.

[TheBearInTheWoods]

I think that any opportunity to buy at these depressed levels before first dose of Phase III is a gift.

[GoldenArm]

This is just the beginning and all signs are positive. Speculators jumped ship and weak hands bailed as well. Good for me in getting more shares. What to look forward to: Sunnybrook Research Institute (SRI) is the sponsor of the CATCO trial. SRI has entered into a collaboration agreement with Arch Biopartners to use LSALT in a new arm of the CATCO trial. SRI and CATCO leadership will now seek

[stocksarefun]

No concern whatsoever about fundamentals. based on the achievements in the last 18 months, this should be a $15 stock if not more right now.  The question is... why isn't it, and what forces are at work to prevent that from happening. There are a dozen stocks in my portfolio that I feel are >50% undervalued. But is patience our only antidote?

[Antonius2]

Large institutions are constrained by covenant issues regarding drugs in phase II and also by the thin float. Once phase II trials are independently verified - we should see substantial volume movement with upward price activity to align us with a proper valuation.